KALA BIO, Inc. announced on February 12, 2025, a leadership transition with the resignation of Chief Executive Officer Mark Iwicki. Todd Bazemore, who previously served as KALA’s President and Chief Operating Officer, has been appointed as the interim CEO, effective immediately. Mr. Iwicki will continue his involvement with the company by serving as Chair of the Board of Directors.
Mr. Bazemore brings over 30 years of experience in the pharmaceutical industry, spanning from ultra-rare orphan diseases to large primary care conditions. He has been with KALA since November 2017 as Chief Operating Officer and as President since December 2021, providing a seamless transition in leadership. His extensive background includes executive roles at Santhera Pharmaceuticals and Dyax Corp.
The company emphasized its commitment to advancing its lead product candidate, KPI-012, for persistent corneal epithelial defect (PCED), as it approaches topline data from the Phase 2b clinical trial in the second quarter of 2025. The leadership change is positioned to support the completion of the CHASE trial and the continued development of KALA's mesenchymal stem cell secretome (MSC-S) platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.